Providing a VOICE for Kansas' MULTIDISCIPLINARY CANCER CARE TEAMs and the PATIENTS THEY SERVE since 1994
Meetings & Education
Financial Advocacy & Patient Assistance
State & Federal Resources
Off-Label Use Literature
Find A Clinical Trial
Patient Advocacy Organizations
National Professional Organizations
KaSCO Corporate Members
Become a Corporate Member
Industry News Archive
FDA Expands Pembrolizumab Indication to Include First-Line NSCLC Treatment
On April 11, 2019, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck Inc.) for the first-line treatment of patients with stage III non-small cell lung cancer (NSCLC) who are not candidates for surgical resection or definitive chemoradiation or metastatic NSCLC. Patients’ tumors must have no EGFR or ALK genomic aberrations and express PD-L1 (Tumor Proportion Score [TPS] ≥1%) determined by an FDA-approved test.
Read the FDA press release here.
Tweets by OSSatACCC